Diagnosis and Management of Iron Deficiency Anemia

Clinical Significance of Laboratory Patterns

• The World Health Organization defines anemia as a hemoglobin level below 12 g/dL in non-pregnant women, and a hemoglobin level of 11.6 g/dL meets this criteria, indicating mild anemia in this population 1, 2
• Low MCH (mean corpuscular hemoglobin) is the most sensitive early marker of iron deficiency, reflecting reduced hemoglobin content in newly produced red cells, with a value of 26.4 pg indicating iron-deficient erythropoiesis 2
• Low MCHC (mean corpuscular hemoglobin concentration) confirms hypochromia, indicating red cells contain less hemoglobin per unit volume than normal, with a value of 30.9 g/dL suggesting iron deficiency 2

Required Diagnostic Workup

• Serum ferritin is the single most useful test to confirm iron deficiency, with levels below 30 μg/L indicating iron deficiency in the absence of inflammation, according to the American Gastroenterological Association 3, 2
• Transferrin saturation below 15-16% supports iron deficiency and is less affected by acute inflammation than ferritin, as recommended by the European Crohn’s and Colitis Organisation 4, 3, 2
• Measuring C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR) helps assess for inflammation, which can falsely elevate ferritin levels and mask true iron deficiency, as suggested by the American College of Gastroenterology 4, 2

Investigation for Underlying Cause

• In premenopausal women, menstrual blood loss is the most common cause of iron deficiency, but gastrointestinal sources must be considered if menstrual losses seem inadequate to explain the deficiency, according to the National Institute of Diabetes and Digestive and Kidney Diseases 3, 1
• Assessing for gastrointestinal blood loss by taking a careful history of nonsteroidal anti-inflammatory drug (NSAID) use, gastrointestinal symptoms, and dietary factors is essential, as recommended by the American Gastroenterological Association 3, 1
• Considering celiac disease screening with tissue transglutaminase (tTG) antibody testing is important, as malabsorption is a significant cause of iron deficiency, with a prevalence of approximately 5% in iron deficiency anemia, according to the Celiac Disease Foundation 3, 1

Treatment Approach

• Oral iron supplementation is the first-line therapy for patients with mild anemia (hemoglobin above 10 g/dL), typically 100 mg elemental iron daily, as recommended by the American College of Gastroenterology 4, 1
• Parenteral (intravenous) iron should be considered if oral iron is not tolerated due to gastrointestinal side effects or if there is malabsorption, according to the European Crohn’s and Colitis Organisation 4, 1
• Blood transfusion is not indicated for mild anemia, as it should be reserved for symptomatic anemia with cardiovascular instability, such as fatigue, hypotension, or tachycardia, as recommended by the American Academy of Orthopaedic Surgeons 5

Monitoring and Follow-up

• Rechecking hemoglobin and iron studies after 1-3 months of iron supplementation is necessary to assess response, as suggested by the American College of Gastroenterology 2
• Continuing iron supplementation for 3-6 months after hemoglobin normalizes is essential to replenish body iron stores, according to the World Health Organization 1
• Monitoring for recurrence is crucial, as anemia recurs in more than 50% of patients within one year, often indicating ongoing blood loss or inadequate iron stores, as recommended by the European Crohn’s and Colitis Organisation 4

Guideline for Evaluating Mild Anemia in Adolescent Females

Epidemiology and Risk Factors

Definition of Mild Anemia

Diagnostic Evaluation

First‑Line Iron Studies

Additional Helpful Tests

Staging of Iron Deficiency

Clinical Pitfalls to Avoid

Alternative Causes When Iron Studies Are Normal

Evaluation and Management of Mild Anemia in Adolescents – Evidence‑Based Recommendations

Epidemiology

• Iron deficiency affects approximately 7.8 million adolescent females and women of child‑bearing age in the United States, with prevalence exceeding 50 % in certain adolescent cohorts due to menstrual blood loss, rapid growth, and inadequate dietary iron intake. [CDC, MMWR Recommendations and Reports 1998] 10

Initial Treatment and Monitoring

• After confirming iron deficiency, re‑measure hemoglobin four weeks after initiating oral iron therapy; an increase of ≥1 g/dL indicates true iron‑deficiency anemia and an adequate therapeutic response. [CDC, MMWR Recommendations and Reports 1998] 10

• If hemoglobin does not rise despite documented adherence to iron supplementation, screen for celiac disease (tissue transglutaminase antibodies) and evaluate for gastrointestinal blood loss to identify alternative or concurrent sources of iron loss. [CDC, MMWR Recommendations and Reports 1998] 10

Evaluation When Iron Studies Are Normal

• In patients with persistent anemia but normal iron studies, perform hemoglobin electrophoresis when microcytosis is present and the individual belongs to an at‑risk ethnic group (e.g., African, Mediterranean, Southeast Asian ancestry) to rule out thalassemia or other hemoglobinopathies. [CDC, MMWR Recommendations and Reports 1998; Gut 2021] [10][11]

Role of AST Measurement in Excluding Liver Disease When Evaluating Anemia

Diagnostic Laboratory Assessment

• In adolescents presenting with mild anemia, a normal aspartate aminotransferase (AST) level (e.g., 11 IU/L) effectively rules out liver disease as a contributing cause, since hepatic disorders such as alcoholic liver disease typically raise AST 2–6‑fold above the upper limit of normal. This interpretation is supported by hepatology evidence. 12

Management of Iron‑Deficiency Anemia in Adolescent Females

Initial Laboratory Evaluation

• Order a complete iron panel (serum ferritin, transferrin saturation, serum iron, TIBC) together with C‑reactive protein, and begin oral iron (60–120 mg elemental iron daily) while awaiting results. [@1]
• Serum ferritin < 30 µg/L confirms iron deficiency when inflammation is absent. [@2]
• Transferrin saturation < 15–16 % supports iron deficiency and is less influenced by acute‑phase reactions than ferritin. [@2]

Empiric Iron Therapy

• Prescribe 60–120 mg elemental iron per day (one to two 60‑mg tablets) taken between meals to maximize absorption. [@1][@3]
• A rise in hemoglobin of ≥1 g/dL (or hematocrit increase ≥3 %) within 4 weeks of therapy confirms iron‑deficiency anemia even if baseline iron studies are equivocal. [@2][@3]

Response Assessment and Follow‑Up

• Re‑measure hemoglobin/hematocrit at 4 weeks; an increase meeting the above thresholds validates the diagnosis and warrants continuation of therapy for an additional 3 months (total 4 months) to replenish iron stores. [@1][@3]
• If hemoglobin does not rise despite documented adherence, obtain hemoglobin electrophoresis (especially in patients of African, Mediterranean, or Southeast Asian ancestry) to exclude thalassemia trait. [@1]

Dietary Recommendations During Iron Therapy

• Advise consumption of iron‑rich foods (red meat, poultry, fish, fortified cereals, beans, lentils) and vitamin‑C‑rich foods (citrus, tomatoes) to enhance absorption. [@1][@3]

Interpretation of Red‑Cell Indices

• Do not rely on a normal mean corpuscular volume (MCV) to exclude iron deficiency; the mean corpuscular hemoglobin (MCH) typically falls before MCV in early deficiency. [@2]

CDC Guidelines for Evaluation and Management of Mild Microcytic Anemia in Adolescent Females

Diagnostic Evaluation

• Order a complete iron panel (serum ferritin, transferrin saturation, serum iron, and total iron‑binding capacity) together with C‑reactive protein, and begin oral ferrous sulfate 60 mg daily while awaiting results. The combined testing accounts for possible inflammation that can mask iron deficiency, and early empiric therapy is recommended for mild anemia in this age group. 13
• Serum ferritin < 30 µg/L confirms depleted iron stores when inflammation is absent. Ferritin is the single most powerful single test for iron deficiency under non‑inflammatory conditions. 13
• Transferrin saturation < 15–16 % supports iron deficiency and is less affected by inflammation than ferritin. Low TSAT adds diagnostic confidence when ferritin interpretation is uncertain. 13

Treatment Initiation

• Prescribe oral ferrous sulfate 60 mg elemental iron once daily, taken on an empty stomach between meals to maximize absorption. This dosage is recommended for adolescent females with mild anemia by CDC guidelines. 13
• Provide dietary counseling to include iron‑rich foods such as red meat, poultry, fish, fortified cereals, beans, and lentils. Enhancing dietary iron intake complements pharmacologic therapy. 13

Follow‑up and Monitoring

• Re‑measure hemoglobin and hematocrit at 4 weeks; an increase of ≥1 g/dL (or hematocrit rise ≥3 %) confirms iron‑deficiency anemia even if baseline iron studies were equivocal. This therapeutic response validates the diagnosis and justifies continuation of therapy for an additional three months (total four‑month course) to fully replenish iron stores. 13

Evaluation of Non‑response

• If no hematologic response after 4 weeks, order hemoglobin electrophoresis to exclude thalassemia trait. Thalassemia minor typically shows RDW ≤ 14 % (versus > 14 % in iron deficiency), normal or borderline iron studies, and an MCV disproportionately low relative to the degree of anemia. 13

Strength of evidence: Not explicitly graded in the cited CDC MMWR recommendations.

Diagnostic Indicators and Management of Iron‑Deficiency Anemia (Cited Evidence)

Red‑Cell Indices

• Elevated red‑cell distribution width (RDW) is a highly suggestive marker of iron‑deficiency anemia and helps differentiate it from thalassemia trait. This finding is based on population studies showing increased anisocytosis in iron deficiency compared with thalassemia. Strength of evidence not specified. 14

• A complete blood count with mean corpuscular volume (MCV) is essential to identify microcytic anemia, which further supports a diagnosis of iron deficiency. Microcytosis in the setting of low iron stores increases the likelihood that the anemia is due to iron deficiency rather than other causes. Strength of evidence not specified. 15

Bone‑Marrow Response

• Reticulocyte count evaluates bone‑marrow activity; a low or inappropriately normal reticulocyte count indicates impaired red‑cell production consistent with iron‑deficiency anemia. This laboratory parameter helps confirm that the anemia is not due to adequate marrow compensation. Strength of evidence not specified. 15

Therapeutic Considerations

• Intravenous iron should be considered when oral iron is poorly tolerated, when malabsorption (e.g., celiac disease) is present, or when rapid iron repletion is clinically required. Intravenous formulations provide a faster and more reliable increase in iron stores under these circumstances. Strength of evidence not specified. 16